Abstract
Development of tears in the retinal pigment epithelium (RIP) has been described as a possible complication following anti-vascular endothelial growth factor (VEGF) antibody therapy with substances which have been available for years when treating pigment epithelium detachment (PED) in eyes affected by age-related macular degeneration (AMD). Aflibercept has become available for the treatment of exsudative AMD since December 2012. This case report describes a further patient in addition to the only other case published so far who developed RIP after aflibercept treatment for PED. Patients have to be thoroughly informed about this potential side effect before initiation of intravitreal aflibercept injection therapy.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Female
-
Humans
-
Intravitreal Injections / adverse effects
-
Macular Degeneration / complications*
-
Macular Degeneration / drug therapy*
-
Receptors, Vascular Endothelial Growth Factor / administration & dosage*
-
Receptors, Vascular Endothelial Growth Factor / adverse effects*
-
Recombinant Fusion Proteins / administration & dosage*
-
Recombinant Fusion Proteins / adverse effects*
-
Retinal Detachment / chemically induced*
-
Retinal Detachment / therapy
-
Retinal Perforations / chemically induced*
-
Retinal Perforations / diagnosis
-
Retinal Perforations / therapy
-
Treatment Outcome
Substances
-
Recombinant Fusion Proteins
-
aflibercept
-
Receptors, Vascular Endothelial Growth Factor